Hainan Huluwa Pharmaceutical Group Co Ltd (605199) — Capital Reinvestment Ratio
Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥44.34 Million) in capital expenditures (CN¥9.15 Million). See 605199 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hainan Huluwa Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2016–2025)
This chart tracks Hainan Huluwa Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
Year-by-year Capital Reinvestment Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. For live market cap and broader valuation context, see Hainan Huluwa Pharmaceutical Group Co Lt (605199) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.61x | CN¥136.85 Million | CN¥83.67 Million | ▼ -96.5% |
| 2023 | 17.32x | CN¥28.25 Million | CN¥489.20 Million | ▲ +953.6% |
| 2022 | 1.64x | CN¥238.71 Million | CN¥392.32 Million | ▲ +22.4% |
| 2021 | 1.34x | CN¥102.48 Million | CN¥137.62 Million | ▼ -92.5% |
| 2020 | 18.01x | CN¥3.30 Million | CN¥59.42 Million | ▲ +4355.8% |
| 2019 | 0.40x | CN¥144.51 Million | CN¥58.40 Million | ▼ -82.4% |
| 2018 | 2.29x | CN¥31.80 Million | CN¥72.82 Million | ▲ +30.7% |
| 2017 | 1.75x | CN¥89.96 Million | CN¥157.58 Million | ▲ +177.6% |
| 2016 | 0.63x | CN¥64.96 Million | CN¥40.99 Million | — |